Pucotenlimab Combined with MRG002 for HER2-positive Cancer of Unknown Primary
NCT06869174
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
50
Enrollment
OTHER
Sponsor class
Conditions
Cancer of Unknown Primary
Interventions
DRUG:
Pucotenlimab combined with MRG002
Sponsor
Zhiguo Luo, MD, PhD